Novarock Biotherapeutics Ltd.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.novarockbio.com
A Study of NBL-028 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- NovaRock Biotherapeutics, Ltd
- Target Recruit Count
- 270
- Registration Number
- NCT06223256
- Locations
- 🇨🇳
No.896 East Zhongshan Road, Shijiazhuang, Hebei Province, China., Shijiazhuang, Hebei, China
A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.
Phase 1
Recruiting
- Conditions
- Advanced Malignant Tumors
- Interventions
- Drug: NBL-020 for Injection
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- NovaRock Biotherapeutics, Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT05877924
- Locations
- 🇨🇳
Wu Yilong, Guanzhou, Guangdong, China
A Study of NBL-012 in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: NBL-012 InjectionDrug: Placebo
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- NovaRock Biotherapeutics, Ltd
- Target Recruit Count
- 52
- Registration Number
- NCT05259189
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University., Suzhou, Jiangsu, China
Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- NovaRock Biotherapeutics, Ltd
- Target Recruit Count
- 410
- Registration Number
- NCT05153096
- Locations
- 🇨🇳
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath